Gemcitabine

製品コードS1714 別名:LY-188011, NSC 613327

Gemcitabine 化学構造

分子量(MW):263.2

Gemcitabineは一種の有効で、特異性的なデオキシシチジン(deoxycytidine)類似物で、、化学療法として使用されることです。

サイズ 価格(税別)  
JPY 21580.00
JPY 16102.00

カスタマーフィードバック(4)

  • Mice were administered either vehicle, gemcitabine (120 mg/kg [PaCa2]) or 20 mg/kg of BBI608 i.p. After killing, tumors were collected after 7 or 14 d of treatment, for Paca-2 and FaDu cells, respectively. Single-cell suspensions were obtained after animal killing and sterile removal of tumors. Live cells were then counted and used to measure their ability to form spheres when cultured in cancer stem cell media.

    Proc Natl Acad Sci USA, 2015, 112(6): 1839-44. Gemcitabine purchased from Selleck.

    RNA incorporating drugs induce SG assembly. HeLa cells were treated with the RNA incorporating agents 5-azacytidine (50 uM) and 6-thioguanine (10 uM), or the DNA incorporating agents trifluorothymidine (10 uM) and gemcitabine (100 nM) for 72 h. Subsequently, the cellular localization of the SG marker protein TIAR (green) and the P-body marker protein DCP1 (red) was analyzed. Nuclei were stained with Hoechst. Scale bars represent 20 um.

    Nucleic Acids Res 2014 42(10), 6436-47. Gemcitabine purchased from Selleck.

  • Immunofluorescent analysis of gemcitabine-induced γH2A.X and 53-BP1 focus formation. a, b Immunofluorescence staining of γH2A.X(green), 53-BP1 (red), and nuclei staining with DAPI (blue) in T24 (a) and T24r GEMCI20 (b) cells after the indicated treatments. Scale bar = 50 μm

    J Exp Clin Cancer Res, 2017, 36(1):1. Gemcitabine purchased from Selleck.

    Cells were seeded in 96 well paltes, and then treated with the indicated concentration of Gemcitabine for 48h. Cell survival was measured by a standarad MTT assay.

    Dr. Helen Sadik of Johns Hopkins University. Gemcitabine purchased from Selleck.

製品安全説明書

DNA/RNA Synthesis阻害剤の選択性比較

生物活性

製品説明 Gemcitabineは一種の有効で、特異性的なデオキシシチジン(deoxycytidine)類似物で、、化学療法として使用されることです。
体外試験

Gemcitabine results in 50% inhibition of growth in the CCRF-CEM human leukemia cell culture assay with IC50 of 1 ng/ml. Gemcitabine combined with deoxycytidine provides about a 1000-fold decrease in biological activity. [1] Gemcitabine combined with C225 results in additive cytotoxic effects that increased with increasing gemcitabine concentrations in human pancreatic carcinoma L3.6pl cells. [2] Gemcitabine combined with Cisplatin results in synergistic effect in wild-type A2780 and cisplatin-resistant ADDP cells. [3]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV-4-11 MnnOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFqwVVJKSzVyPUCuNFAxPDV6IH7N MWPTRW5ITVJ?
ES4 NUPqfIxST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2GyfGlEPTB;MD6wNFA3PTNibl2= MWDTRW5ITVJ?
ACHN NHfMTYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHW3[5FKSzVyPUCuNFAxQDh5IH7N NWHoOI83W0GQR1XS
KYSE-510 M1XkVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmW4TWM2OD1yLkCwNFk4PSCwTR?= MlO5V2FPT0WU
EW-7 NIn0fZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1ixUmlEPTB;MD6wNFI2QCCwTR?= NILwO3FUSU6JRWK=
BFTC-905 NXWyVZVLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XwSWlEPTB;MD6wNFUyPSCwTR?= MlLCV2FPT0WU
KE-37 NVjINYZGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\ITWM2OD1yLkCwOVYyKG6P MkW4V2FPT0WU
SBC-5 MmnzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTBwMEC1O{BvVQ>? MX;TRW5ITVJ?
NKM-1 NE\Td|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIeyXVFKSzVyPUCuNFA4ODlibl2= NUL2WIZQW0GQR1XS
RH-1 NYLnXIV6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTBwMEC3NVghdk1? NWjzXW1EW0GQR1XS
ALL-PO MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHUR|RNUUN3ME2wMlAxQDNibl2= NXGxbJM6W0GQR1XS
QIMR-WIL NFfOWGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlT4TWM2OD1yLkCwPFk1KG6P NYHFUXZGW0GQR1XS
A375 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7rTWM2OD1yLkCwPVk2KG6P MljOV2FPT0WU
SIG-M5 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTvTWM2OD1yLkCxNFQhdk1? M2XGOHNCVkeHUh?=
KGN MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTBwMEGwPEBvVQ>? NVTXdXBwW0GQR1XS
EW-13 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHz1NItKSzVyPUCuNFEyOiCwTR?= NHntOoRUSU6JRWK=
NCI-SNU-1 MoDyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PFZmlEPTB;MD6wNVYhdk1? NUXvb29KW0GQR1XS
PSN1 M4HNT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzxSZZKSzVyPUCuNFE3PSCwTR?= MYXTRW5ITVJ?
HUTU-80 NYTwVZE2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkO5TWM2OD1yLkCxOlYhdk1? NFTaepJUSU6JRWK=
EW-16 Mm\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M320[WlEPTB;MD6wNlMhdk1? NGHyZYNUSU6JRWK=
786-0 M4LDbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TTTWlEPTB;MD6wNlMhdk1? M3XvcXNCVkeHUh?=
ES1 M{LESmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkntTWM2OD1yLkCyOlghdk1? MYXTRW5ITVJ?
RKO NVnnWnBQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXCbodIUUN3ME2wMlAzPzlibl2= M3znfHNCVkeHUh?=
ESS-1 M1rSSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfOUmhDUUN3ME2wMlAzQDZibl2= MXzTRW5ITVJ?
SK-UT-1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTBwMEK5O{BvVQ>? MWTTRW5ITVJ?
LB2241-RCC NWT5NmN{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTifXNKSzVyPUCuNFMyQCCwTR?= NGftbZhUSU6JRWK=
CHL-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjEdYc{UUN3ME2wMlA{OjRibl2= NFTTbZRUSU6JRWK=
SW1783 NIrwdlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPBTWM2OD1yLkCzN|Yhdk1? M2HZcHNCVkeHUh?=
MEL-JUSO MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnzTWM2OD1yLkCzPVEhdk1? MlqwV2FPT0WU
HT-29 NWLsem5uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vN[WlEPTB;MD6wOFE{KG6P NH7PUFFUSU6JRWK=
SNG-M MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHC[|ZQUUN3ME2wMlA1OjVibl2= MkXXV2FPT0WU
TE-15 NGX3PHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPmV45GUUN3ME2wMlA1PjRibl2= M{HMRnNCVkeHUh?=
HOS NFPDRYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH24[IpKSzVyPUCuNFQ5KG6P MofXV2FPT0WU
BB65-RCC NWHsdoUyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfwPXk6UUN3ME2wMlA2OTJibl2= NEfuclBUSU6JRWK=
HCE-4 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjiRYhWUUN3ME2wMlA2Ojhibl2= MWTTRW5ITVJ?
MHH-ES-1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvIfmtIUUN3ME2wMlA2OzFibl2= NWOySnM4W0GQR1XS
RPMI-7951 MlL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTBwMEW0NUBvVQ>? NF\IcZRUSU6JRWK=
IST-SL2 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;mTWM2OD1yLkC1PFQhdk1? M4jCdnNCVkeHUh?=
CMK Mn34S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlH1TWM2OD1yLkC1PFYhdk1? MWfTRW5ITVJ?
GR-ST NFfzSYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGK1U2tKSzVyPUCuNFU6PSCwTR?= Ml;QV2FPT0WU
NALM-6 NH3hUmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTBwME[yNkBvVQ>? MXXTRW5ITVJ?
RPMI-6666 MoPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXXTZRKSzVyPUCuNFY2OiCwTR?= NV\oR5ljW0GQR1XS
LC-2-ad MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPKb|B4UUN3ME2wMlA3PTNibl2= MW\TRW5ITVJ?
ARH-77 NGn3[4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXRUJFKSzVyPUCuNFcyOSCwTR?= NILyU3NUSU6JRWK=
IST-MEL1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWf1fVJmUUN3ME2wMlA4OjZibl2= MXHTRW5ITVJ?
SW1710 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M173cGlEPTB;MD6wO|UyKG6P MmHxV2FPT0WU
DEL MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTBwMEi4O{BvVQ>? MnvDV2FPT0WU
AGS M4HoWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTBwMEmwNkBvVQ>? MnfvV2FPT0WU
NCI-H2122 MlzOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTBwMEm0OkBvVQ>? MXPTRW5ITVJ?
HSC-4 MkjNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXpTWM2OD1yLkGwNkBvVQ>? MnzKV2FPT0WU
AM-38 MmjXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPRUVdKSzVyPUCuNVIyKG6P M2TJXXNCVkeHUh?=
769-P NXrWWGJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTBwMUKzJI5O NVvrOHY5W0GQR1XS
RT-112 Ml3xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrv[Zg4UUN3ME2wMlEzPyCwTR?= M3zpNXNCVkeHUh?=
MCF7 NIqxToxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTBwMUO2JI5O MlvxV2FPT0WU
IGROV-1 MljuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTBwMUS1JI5O NXGzZ4VZW0GQR1XS
OCI-AML2 NEHJeGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfCcZpKSzVyPUCuNVQ4KG6P NH;hZYlUSU6JRWK=
NCI-H1299 NG\CPY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnMO4tKSzVyPUCuNVU4KG6P NFPDc2FUSU6JRWK=
A431 MnLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTBTWM2OD1yLkG4N{BvVQ>? MU\TRW5ITVJ?
SW982 M1zCNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTBwMkGzJI5O NHXnUlhUSU6JRWK=
BB30-HNC MmjtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPFTWM2OD1yLkKzNUBvVQ>? M3TUPXNCVkeHUh?=
ACN M4Dmb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jETGlEPTB;MD6yOFQhdk1? MnXSV2FPT0WU
647-V NGrVOohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjqeGZKSzVyPUCuNlQ5KG6P MWDTRW5ITVJ?
SK-PN-DW M2fYNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDMNpdJUUN3ME2wMlI3PiCwTR?= NUXROI12W0GQR1XS
LCLC-97TM1 NV;6c5VFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\LTWM2OD1yLkK2O{BvVQ>? MVzTRW5ITVJ?
LB1047-RCC MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\tOmlEPTB;MD6yOlkhdk1? NELMcWhUSU6JRWK=
A2780 M3zDR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDGUnhCUUN3ME2wMlI4KG6P NW[2N3hpW0GQR1XS
C-33-A MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rKUmlEPTB;MD6yO|Mhdk1? MV3TRW5ITVJ?
NCI-H2228 M{XQU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\3OplKSzVyPUCuN|E1KG6P M2jzXHNCVkeHUh?=
TE-5 MlX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjlV3lKSzVyPUCuN|E3KG6P M3viRXNCVkeHUh?=
HC-1 M{XlfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvPZ|NKSzVyPUCuN|I4KG6P MlPsV2FPT0WU
SK-MES-1 M3TIdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTBwM{K4JI5O MorxV2FPT0WU
NCI-H1355 M2iwdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTBwM{ixJI5O NFHVPWJUSU6JRWK=
YKG-1 MljVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUD0SIxpUUN3ME2wMlQyQSCwTR?= NY\ZU292W0GQR1XS
RS4-11 NXHxTW9QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\yTG5XUUN3ME2wMlQ{OyCwTR?= NHrp[|ZUSU6JRWK=
Daoy M17ITmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELEPZFKSzVyPUCuOFU3KG6P NFHJboZUSU6JRWK=
A3-KAW MmLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXYZXNKSzVyPUCuOVUyKG6P M4TiPXNCVkeHUh?=
SK-MEL-30 NGjkfXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fZemlEPTB;MD61OVQhdk1? MmH0V2FPT0WU
U031 NF34eZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrOOXJ2UUN3ME2wMlU3PSCwTR?= Mn3iV2FPT0WU
SK-LMS-1 NIHMeo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\W[|NKSzVyPUCuOVc5KG6P NFnzVo5USU6JRWK=
ES6 NVL1Tod{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2j2d2lEPTB;MD61PFYhdk1? MnH1V2FPT0WU
EoL-1-cell NF;uU|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTBwNkG2JI5O NILBRYtUSU6JRWK=
NCI-H2009 M1nSOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4D6XmlEPTB;MD62NVkhdk1? NIDyb5BUSU6JRWK=
A4-Fuk M1T3bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PWRmlEPTB;MD62NlYhdk1? NEWw[JRUSU6JRWK=
KYSE-270 M2m1UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHVTWM2OD1yLk[zOEBvVQ>? NUTmO45wW0GQR1XS
SK-LU-1 NX3GZVExT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDOTWM2OD1yLk[1OUBvVQ>? MmP0V2FPT0WU
SW872 M3fvSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYD5eXNTUUN3ME2wMlc3PSCwTR?= MUnTRW5ITVJ?
ES8 MliwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;Y[GlEPTB;MD63PEBvVQ>? M1fERnNCVkeHUh?=
G-402 MlfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHMeJpvUUN3ME2wMlc5PCCwTR?= NVzvfVZPW0GQR1XS
ATN-1 NWrDVXVzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LJXWlEPTB;MD64NFchdk1? MWjTRW5ITVJ?
DoTc2-4510 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LuXGlEPTB;MD65NFEhdk1? NGHtTWxUSU6JRWK=
MES-SA MojUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXFd|ZKSzVyPUCuPVA2KG6P NEnYemlUSU6JRWK=
SF268 NUfVOGpLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2P6Z2lEPTB;MD65Nlchdk1? NWfFcHlxW0GQR1XS
SF539 NEXtfmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\LcpJKSzVyPUGuNFIhdk1? MYjTRW5ITVJ?
NB69 NYj5dVVbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrIfpFKSzVyPUGuNFUhdk1? MX7TRW5ITVJ?
8505C MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTFwME[gcm0> MXHTRW5ITVJ?
CAL-12T MnK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfkZYlKSzVyPUGuNFghdk1? M2TXbnNCVkeHUh?=
BHY NITze5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYj3Too4UUN3ME2xMlE1KG6P M4PTUXNCVkeHUh?=
LB647-SCLC MnflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnnTWM2OD1zLkG4JI5O NEjIXIJUSU6JRWK=
CAL-62 M2\hTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXr1[486UUN3ME2xMlIzKG6P MnnSV2FPT0WU
MEG-01 NUj0d4d5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLUbnZuUUN3ME2xMlI4KG6P NWfW[WJQW0GQR1XS
MG-63 MnK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfpPWdKSzVyPUGuN|Mhdk1? M4fwWHNCVkeHUh?=
SW620 MmrnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVToUHJ6UUN3ME2xMlM2KG6P NVvQV4FtW0GQR1XS
A388 MmDHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\vVWlEPTB;MT6zOkBvVQ>? Ml\SV2FPT0WU
BCPAP NIPQb2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzKTWM2OD1zLkS1JI5O MnzFV2FPT0WU
P30-OHK NUTTN3BCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXm2NY5wUUN3ME2xMlQ3KG6P MYrTRW5ITVJ?
Ca9-22 MoP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlywTWM2OD1zLkW0JI5O MVnTRW5ITVJ?
VMRC-RCZ MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3y4UGlEPTB;MT61OEBvVQ>? M{jNd3NCVkeHUh?=
LOXIMVI NXzve49nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTFwNjDuUS=> MWTTRW5ITVJ?
L-540 M{\2cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrYbWFvUUN3ME2xMlYhdk1? NXHTWmZCW0GQR1XS
NTERA-S-cl-D1 Mnv2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfsO4xKSzVyPUGuOlQhdk1? NH3nNWlUSU6JRWK=
MFH-ino MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnm4TWM2OD1zLk[2JI5O M{f1e3NCVkeHUh?=
Calu-6 MkHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4frc2lEPTB;MT63N{BvVQ>? MYnTRW5ITVJ?
HEL NGLMPJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXTUnVVUUN3ME2xMlc6KG6P NF;XVnJUSU6JRWK=
CAL-33 NFTUeXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DGSmlEPTB;MT64PUBvVQ>? NUPv[lRxW0GQR1XS
HSC-3 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkL0TWM2OD1zLkmxJI5O NXTySph5W0GQR1XS
KU812 NV7FTWpRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkSwTWM2OD1zLkmxJI5O M4fiPXNCVkeHUh?=
EB2 Mn;SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPhPXNKSzVyPUKuNFEhdk1? NFPS[mxUSU6JRWK=
SR NY\DUHhuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3kWYVwUUN3ME2yMlEzKG6P NFrMR5BUSU6JRWK=
NCI-H2087 MnjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUj6dndTUUN3ME2yMlE1KG6P M4nyPHNCVkeHUh?=
H4 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTJwMUigcm0> NIX1TZNUSU6JRWK=
EW-1 MlXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjZUoJKSzVyPUKuNlIhdk1? M17GVHNCVkeHUh?=
MC-IXC M3W5OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmriTWM2OD1{LkK2JI5O NFnV[mFUSU6JRWK=
NCI-H727 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTJwNUGgcm0> MkHXV2FPT0WU
MRK-nu-1 MoDnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DHdWlEPTB;Mj61O{BvVQ>? NWS4eHB4W0GQR1XS
COLO-668 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHySZBSUUN3ME2yMlY3KG6P NWjOb4VzW0GQR1XS
CGTH-W-1 M1;LSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rVVWlEPTB;Mj63NkBvVQ>? NEfjVodUSU6JRWK=
CHP-212 M4TabGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTOepRKSzVyPUKuO|Uhdk1? NUPwPVh7W0GQR1XS
GI-1 NFj5XIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlj1TWM2OD1{Lke2JI5O NHHY[mpUSU6JRWK=
HCC1806 NGPkNVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7mTWM2OD1{LkmxJI5O NGjrV4tUSU6JRWK=
HLE MlrwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfFZlFKSzVyPUOgcm0> M4j2S3NCVkeHUh?=
HSC-2 NYLPfGtKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DVR2lEPTB;Mz6wN{BvVQ>? MnXVV2FPT0WU
DMS-273 M4fiZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\3TWM2OD1|LkC3JI5O MlnVV2FPT0WU
DU-4475 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nPXWlEPTB;Mz6xOEBvVQ>? M12zTnNCVkeHUh?=
LXF-289 M{PyOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTNwM{Ggcm0> NFrqNpNUSU6JRWK=
PANC-03-27 MoLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnMWZZMUUN3ME2zMlUyKG6P MmTNV2FPT0WU
GAMG NGDnOpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\q[ohKSzVyPUOuO|Qhdk1? MoGxV2FPT0WU
NCI-H522 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljYTWM2OD12LkO0JI5O MXHTRW5ITVJ?
SW626 NHzqTGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jNUWlEPTB;ND60OkBvVQ>? M3P3bHNCVkeHUh?=
HT-144 NXX1VnpbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHNTWM2OD12LkmyJI5O NVXsdFhjW0GQR1XS
MEL-HO MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTVwMU[gcm0> NXr4WGt{W0GQR1XS
BE-13 M1HrcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7xd|NKSzVyPUWuNlEhdk1? MkjnV2FPT0WU
VA-ES-BJ NELE[pBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHpNYpmUUN3ME21MlI3KG6P NEX4TGpUSU6JRWK=
NCI-H441 MnTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUCxcXpMUUN3ME21MlYhdk1? MnPkV2FPT0WU
KP-4 MnnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLlTWM2OD13Lk[xJI5O MXLTRW5ITVJ?
LoVo MkjrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTVwN{Ggcm0> NEHCTINUSU6JRWK=
HT-1080 NE\udY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrL[3B5UUN3ME21Mlg{KG6P MV\TRW5ITVJ?
GB-1 NWXkTWI3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HVd2lEPTB;NT64OEBvVQ>? NWDTbJNCW0GQR1XS
IA-LM MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULWV45UUUN3ME21MlkyKG6P NHvCbYtUSU6JRWK=
8-MG-BA MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mkj1TWM2OD13LkmzJI5O NF;ERm5USU6JRWK=
SK-HEP-1 MkLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTZwMUSgcm0> NYLUWo02W0GQR1XS
697 M4PhbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrkR5hKSzVyPU[uNlUhdk1? Mn3nV2FPT0WU
KYSE-450 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTZwM{Kgcm0> NFvRWnJUSU6JRWK=
HCC2998 MnzYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjuTnBKSzVyPU[uN|Qhdk1? MVPTRW5ITVJ?
HD-MY-Z M2DhUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\vTWM2OD14Lk[4JI5O M3HDNXNCVkeHUh?=
OS-RC-2 M{LNfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXL3cY01UUN3ME22MlY5KG6P NFrYc21USU6JRWK=
SF126 M3HsZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjtTWM2OD15LkC1JI5O M17aU3NCVkeHUh?=
Ca-Ski MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTdwMEmgcm0> NFz6PIFUSU6JRWK=
NCI-H358 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzaVpB7UUN3ME23MlE3KG6P M4DOOHNCVkeHUh?=
J82 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHL0dnpKSzVyPUeuOFEhdk1? NF;WZnBUSU6JRWK=
NCI-H2342 M2PBe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTdwNkOgcm0> NYnqOWRLW0GQR1XS
OVCAR-8 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTdwOTDuUS=> MXLTRW5ITVJ?
TE-8 MnW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHMN3IxUUN3ME24JI5O Ml23V2FPT0WU
ETK-1 NYqz[|VXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRThwMEigcm0> NUnxSmlKW0GQR1XS
HAL-01 MmnMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\aOGdKSzVyPUiuNkBvVQ>? NGrPdnVUSU6JRWK=
KYSE-150 NX63NHRPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPnVmZKSzVyPUiuOFchdk1? MnPXV2FPT0WU
NCI-H810 M17sTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfRTWM2OD16LkW2JI5O NFrtVFBUSU6JRWK=
ONS-76 Mm\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVv0TnFEUUN3ME24MlY5KG6P M4j6NHNCVkeHUh?=
NMC-G1 NXvmfoFrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUX5N5VQUUN3ME24Mlc3KG6P MUfTRW5ITVJ?
C3A M3n3PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRThwOESgcm0> MUPTRW5ITVJ?
PA-1 M4XEdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYiyTYxtUUN3ME24Mlk6KG6P MnvlV2FPT0WU
SH-4 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2n3[WlEPTB;OT6wNkBvVQ>? MXLTRW5ITVJ?
EFO-27 M{\oSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTlwMEWgcm0> MUDTRW5ITVJ?
CAPAN-1 NXX4d3dLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3f2cmlEPTB;OT6yN{BvVQ>? M2XFTXNCVkeHUh?=
DU-145 NWHxRYw3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWflUI1CUUN3ME25MlI6KG6P NUTibHNSW0GQR1XS
A101D M2LuOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXYNYhTUUN3ME25MlM4KG6P M3TTO3NCVkeHUh?=
ST486 NUHhWZI{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTlwNEGgcm0> NV7XZWtmW0GQR1XS
NCI-H1437 NGe5O2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY[xO29YUUN3ME25MlQzKG6P NVLjbG1XW0GQR1XS
HGC-27 Mn3XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrIbXJKSzVyPUmuOkBvVQ>? MXzTRW5ITVJ?
8305C NGD4ZppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LmUGlEPTB;OT62OEBvVQ>? MY\TRW5ITVJ?
OCUB-M NYO2W3dQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTFyLkCzJI5O NXvv[YNsW0GQR1XS
COLO-679 NVH3d246T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTMdFd2UUN3ME2xNE4xPyCwTR?= M{HidXNCVkeHUh?=
Detroit562 Mke3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETNNmdKSzVyPUGwMlQzKG6P MUHTRW5ITVJ?
A204 NFvjXI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zxdGlEPTB;MUGuNVYhdk1? NWfq[WR6W0GQR1XS
NCI-H1734 MmSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vSO2lEPTB;MUGuNlkhdk1? M3jvV3NCVkeHUh?=
MC-CAR NHL3WWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmX1TWM2OD1zMT61PEBvVQ>? MmXKV2FPT0WU
NCI-H2170 NGfKdJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETldWVKSzVyPUGxMlk4KG6P NYPqUWxvW0GQR1XS
NCI-SNU-5 MlrLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\KU2lEPTB;MUKuNVMhdk1? M3rhbnNCVkeHUh?=
HCE-T NX;FNm1sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHjWY9KSzVyPUGyMlQzKG6P MlLxV2FPT0WU
KYSE-180 M1vycmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;2WndZUUN3ME2xNk45OSCwTR?= MYPTRW5ITVJ?
C8166 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTF|LkC4JI5O M{DnOHNCVkeHUh?=
NCI-H460 NEfibmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvOcGdKSzVyPUGzMlU1KG6P NYX1Z4FGW0GQR1XS
SNU-449 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3r5SWlEPTB;MUOuO|chdk1? NEH6b4lUSU6JRWK=
MDA-MB-468 M1jL[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPIS5oxUUN3ME2xOE4yOiCwTR?= MorHV2FPT0WU
COR-L23 M33QOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTF2LkGzJI5O NUDjUVFIW0GQR1XS
CTV-1 NG\pd4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvsbJdKSzVyPUG0MlE1KG6P Ml;1V2FPT0WU
BL-41 MmOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjuTWM2OD1zND6zO{BvVQ>? NWnRTFRKW0GQR1XS
IGR-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXnb2Z4UUN3ME2xOE41OiCwTR?= M4rwPXNCVkeHUh?=
TK10 M4TvdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPORnVKSzVyPUG0MlQ6KG6P NYHJcWsyW0GQR1XS
REH MnzES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TMdGlEPTB;MUSuOVEhdk1? M4n1VnNCVkeHUh?=
LU-139 NEL6dFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTF2LkW5JI5O M2PRRnNCVkeHUh?=
KP-N-YS MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTF2Lkm3JI5O M2OwO3NCVkeHUh?=
PANC-10-05 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTETWM2OD1zNT6zPEBvVQ>? MnvWV2FPT0WU
HL-60 NGfBeYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTF3Lk[5JI5O MWDTRW5ITVJ?
T84 NHrjS4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPhTWM2OD1zNT65OkBvVQ>? MX3TRW5ITVJ?
RPMI-8226 NE\PWGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LwV2lEPTB;MU[uNFIhdk1? NIHzWoxUSU6JRWK=
UM-UC-3 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHHNpNsUUN3ME2xOk4yPiCwTR?= NFzp[ZVUSU6JRWK=
TE-10 NE\mRYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTod41KSzVyPUG2MlIyKG6P MV\TRW5ITVJ?
CAL-148 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvOWHhiUUN3ME2xO{4zOyCwTR?= MY\TRW5ITVJ?
BV-173 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTF5LkK3JI5O NXH5[XdmW0GQR1XS
Calu-3 MoLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPLWVNYUUN3ME2xO{4zQSCwTR?= MYTTRW5ITVJ?
RPMI-2650 Mn7aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTF5LkW5JI5O NYTnXFVrW0GQR1XS
MKN45 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3j2XWlEPTB;MUeuO|Mhdk1? MV;TRW5ITVJ?
NUGC-3 M3q5OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTF6LkO0JI5O NFXsbFhUSU6JRWK=
NCI-H520 NYXwTGQyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTF6Lke3JI5O MoWwV2FPT0WU
CCRF-CEM M3jkPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3WzUGlEPTB;MUiuPFUhdk1? MWLTRW5ITVJ?
NCI-H2405 NEfMd3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DkdGlEPTB;MUmuNUBvVQ>? MlnUV2FPT0WU
ES7 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M130c2lEPTB;MUmuO|Yhdk1? MnWzV2FPT0WU
BPH-1 MofyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVn1O|J2UUN3ME2yNE4zQCCwTR?= NVv2VWl1W0GQR1XS
SAS NHT6VFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1z6O2lEPTB;MkCuOUBvVQ>? NYXCSXV4W0GQR1XS
HuCCT1 M2T2WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXGzT|h[UUN3ME2yNE42QCCwTR?= M4rFV3NCVkeHUh?=
LOUCY MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTJyLk[2JI5O NHHxU5ZUSU6JRWK=
NCI-H292 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTJyLke5JI5O NGLqe2lUSU6JRWK=
G-361 NHvRTIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1ztfmlEPTB;MkGuNFchdk1? Mnz4V2FPT0WU
M059J MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LwUmlEPTB;MkGuNFghdk1? NUfib4NNW0GQR1XS
NCI-H1651 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTJzLkGxJI5O MljLV2FPT0WU
KALS-1 MnjBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLxTWM2OD1{MT6zPUBvVQ>? NIf3UIxUSU6JRWK=
DJM-1 NYm4dY51T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;WTWM2OD1{MT61PUBvVQ>? NH24T2ZUSU6JRWK=
AU565 NXna[lJvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvZeFZDUUN3ME2yNU45OyCwTR?= NVjPWYd[W0GQR1XS
HCC38 NXy0cIZNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYS5TGZbUUN3ME2yNU46PSCwTR?= NHP1WFNUSU6JRWK=
U251 NFfUephIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoWyTWM2OD1{Mj6yO{BvVQ>? NWH0Zmp1W0GQR1XS
ABC-1 M1PMcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XZTWlEPTB;MkKuOlUhdk1? M{PXVHNCVkeHUh?=
SK-NEP-1 NVvmVJJQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfSbWFDUUN3ME2yNk46OyCwTR?= M4DxOXNCVkeHUh?=
CESS NVvTPJh{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrIWodKSzVyPUKzMlE6KG6P MljqV2FPT0WU
MIA-PaCa-2 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTJ|LkO2JI5O NUDhTGhJW0GQR1XS
SUP-T1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1n2[WlEPTB;MkOuOFchdk1? MUPTRW5ITVJ?
L-428 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7TS3M3UUN3ME2yN{43OiCwTR?= M{fVeXNCVkeHUh?=
SW954 MlGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\qWHJKSzVyPUKzMlY5KG6P M3jCPHNCVkeHUh?=
HO-1-N-1 M4ToS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfiTWM2OD1{Mz63O{BvVQ>? NGjuNnRUSU6JRWK=
CHP-126 M2D4Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTJ2LkG0JI5O NUXifVhnW0GQR1XS
HMV-II M3L0PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLQTWM2OD1{ND6zOEBvVQ>? M4XYWnNCVkeHUh?=
NB10 M4jYeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFmzd|NKSzVyPUK0MlM4KG6P MoLhV2FPT0WU
A172 Mki2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVj2XHhFUUN3ME2yOE44OSCwTR?= NX3LVXBZW0GQR1XS
MONO-MAC-6 NYjhZZE2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVy3eJVtUUN3ME2yOE45PCCwTR?= MV3TRW5ITVJ?
NCI-H1650 M2j0OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfMTWM2OD1{NT60JI5O M3LYd3NCVkeHUh?=
NH-12 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzkVIhqUUN3ME2yOU42KG6P M{DmW3NCVkeHUh?=
ML-2 M3HmUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvnTWM2OD1{NT63OEBvVQ>? MXzTRW5ITVJ?
MZ2-MEL NVLjWGlOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTJ4LkKyJI5O M1LzZnNCVkeHUh?=
COLO-684 NXu0XIpHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTKTWM2OD1{Nj60NUBvVQ>? NYrqXo1jW0GQR1XS
HuP-T4 MljxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnKTWM2OD1{Nz6zJI5O MYfTRW5ITVJ?
SW837 NYTGTm9kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTJ5Lk[yJI5O M2\KfXNCVkeHUh?=
MDA-MB-231 MmjUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFmybZNKSzVyPUK3Mlc5KG6P MWPTRW5ITVJ?
KYSE-140 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWr2b2lxUUN3ME2yO{46OSCwTR?= M3;iVnNCVkeHUh?=
NOMO-1 NWLhTo1CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1OxWmlEPTB;MkiuOlghdk1? Mm\tV2FPT0WU
GP5d NYrVZ4pJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nEWGlEPTB;MkiuO|Ihdk1? NUfDdGFCW0GQR1XS
COR-L105 NEfaTY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3sTWM2OD1{OT60NkBvVQ>? NXf3[HViW0GQR1XS
LS-411N M4jvRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTJ7Lki4JI5O M1ewdHNCVkeHUh?=
NY M2H3fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\rS2lwUUN3ME2zNE4yQCCwTR?= NIrPSVVUSU6JRWK=
NCI-H2030 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nROmlEPTB;M{CuOFUhdk1? Ml\1V2FPT0WU
CCF-STTG1 M4DwUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrDUYY2UUN3ME2zNU41OiCwTR?= NUjhc4x2W0GQR1XS
NCI-H1703 NUDkXnlwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jiVGlEPTB;M{GuO|ghdk1? NYnLXWI6W0GQR1XS
TUR NWTuclBCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTMTWM2OD1|Mj6wN{BvVQ>? NF7BSo5USU6JRWK=
NOS-1 MmjkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXz3NXVbUUN3ME2zNk41PCCwTR?= MoXtV2FPT0WU
A2058 NGPBWmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrOOlJKSzVyPUOyMlg{KG6P MlnhV2FPT0WU
LCLC-103H MnvHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\TTI1KSzVyPUOzMlI2KG6P MmDOV2FPT0WU
NCI-H510A NHO4folIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPWWoZtUUN3ME2zN{4zPyCwTR?= NIfOfXhUSU6JRWK=
BC-1 MnfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vPfGlEPTB;M{OuO|chdk1? Mm\yV2FPT0WU
SK-CO-1 M3vSPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTTRlI4UUN3ME2zOE4xOSCwTR?= MU\TRW5ITVJ?
A673 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\Bc2lEPTB;M{SuNVchdk1? NYnhT21qW0GQR1XS
VM-CUB-1 NFHLdYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXqTWM2OD1|ND62PUBvVQ>? M1rZV3NCVkeHUh?=
HH Mk\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDXUoxKSzVyPUO1MlA3KG6P MlPrV2FPT0WU
CAL-27 NUDZVnpqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPKOG1KSzVyPUO1MlE3KG6P NGjReopUSU6JRWK=
NEC8 Mn\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfhd3BKSzVyPUO1MlM4KG6P M4\kSnNCVkeHUh?=
BxPC-3 NWT1ZohvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DOS2lEPTB;M{[uPVEhdk1? MVjTRW5ITVJ?
SNB75 NHr5OnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTN5LkK0JI5O MYDTRW5ITVJ?
NB13 MkLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTN6LkKzJI5O MlrQV2FPT0WU
SK-OV-3 Mon5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXu1TJozUUN3ME2zPE44PCCwTR?= NVrLfo1ZW0GQR1XS
ME-180 M2LIOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEC1XHBKSzVyPUO4Mlghdk1? MYPTRW5ITVJ?
JiyoyeP-2003 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\0VJlFUUN3ME2zPU4{QCCwTR?= MkD3V2FPT0WU
LU-134-A NYLSe|BQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTRyLkCyJI5O Ml3GV2FPT0WU
LS-123 NHnQVplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTRyLkK4JI5O NInvW3FUSU6JRWK=
COLO-800 NUG3PHBPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLYTWM2OD12MD61OkBvVQ>? MWjTRW5ITVJ?
LB831-BLC NIC5cXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTRzLki1JI5O MWfTRW5ITVJ?
NCI-H747 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\4OWlEPTB;NEKuNlghdk1? MWXTRW5ITVJ?
MZ7-mel NUm3eZJHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTrTWM2OD12Mj62OkBvVQ>? MWPTRW5ITVJ?
GT3TKB M371c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELWOW5KSzVyPUSyMlczKG6P NEL0OWlUSU6JRWK=
MOLT-16 MnX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\FfYlKSzVyPUSzMlA2KG6P NWj0U5lNW0GQR1XS
23132-87 M2PUXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTR|LkC1JI5O MVrTRW5ITVJ?
PF-382 Ml3zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmS1TWM2OD12ND6yNkBvVQ>? M1TKN3NCVkeHUh?=
ES3 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPpfY5oUUN3ME20OE43KG6P MoC1V2FPT0WU
SW756 NEjsW4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUL0SXRiUUN3ME20OU4yPCCwTR?= M1HBUnNCVkeHUh?=

多くの細胞株試験データを見る場合、クリックしてください

体内試験 Gemcitabine combined with C225 results in growth inhibition, tumor regression, and abrogation of metastasis in L3.6pl tumors established in the pancreas of nude mice. Gemcitabine treatment alone reduces median tumor volume from 538 to 152 mm3. Gemcitabine reduces the production of vascular endothelial growth factor and interleukin 8 in gemcitabine-treated tumors. [2] Gemcitabine is able to dramatically and specifically reduces the number of myeloid suppressor cells found in the spleens of animals bearing large tumors with no significant reductions in CD4(+) T cells, CD8(+) T cells, NK cells, macrophages, or B cells. [4] Gemcitabine combined with curcumin shows significant reductions in volume (P = 0.008 versus control; P = 0.036 versus gemcitabine alone), Ki-67 proliferation index (P = 0.030 versus control), NF-kappaB activation, and expression of NF-kappaB-regulated gene products (cyclin D1, c-myc, Bcl-2, Bcl-xL, cellular inhibitor of apoptosis protein-1, cyclooxygenase-2, matrix metalloproteinase, and vascular endothelial growth factor) compared with tumors from control mice treated with olive oil only. Gemcitabine combined with Curcumin is also highly effective in suppressing angiogenesis as indicated by a decrease in CD31(+) microvessel density. [5]

お薦めの試験操作(参考用のみ)

溶解度 (25°C)

体外 DMSO 52 mg/mL (197.56 mM)
Water 52 mg/mL warmed (197.56 mM)
Ethanol Insoluble
体内 順序で溶剤を入れること:
water warming
14mg/mL

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 263.2
化学式

C9H11F2N3O4

CAS No. 95058-81-4
保管
別名 LY-188011, NSC 613327

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02181634 Active, not recruiting Cholangiocarcinoma PrECOG, LLC.|Celgene Corporation December 9, 2014 Phase 2
NCT01535924 Recruiting Adult Lymphocyte Depletion Hodgkin Lymphoma|Adult Lymphocyte Predominant Hodgkin Lymphoma|Adult Mixed Cellularity Hodgkin Lymphoma|Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma|Adult Nodular Sclerosis Hodgkin Lymphoma|Recurrent Adult Hodgkin Lymphoma Kristie Blum|Ohio State University Comprehensive Cancer Center February 9, 2012 Phase 1|Phase 2
NCT01285037 Recruiting Cancer Eli Lilly and Company September 9, 2009 Phase 1
NCT01828736 Completed Recurrent Bladder Cancer|Stage IV Bladder Cancer|Transitional Cell Carcinoma of the Bladder Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie|Roche Pharma AG February 9, 2004 Phase 2
NCT01352962 Active, not recruiting Urethral Neoplasms|Neoplasms, Urethral|Ureter Cancer|Cancer of the Urethra|Urethral Cancer National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) April 5, 2011 Phase 1
NCT03027284 Recruiting Advanced Cancer|Metastatic Cancer|Biliary Tract Carcinoma|Cholangiocarcinoma|Gall Bladder Carcinoma|Solid Tumor|Non-Hodgkins Lymphoma Eli Lilly and Company February 3, 2017 Phase 1

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

よくある質問(FAQ)

  • 問題1:

    What is the difference between gemcitabine(S1714 ) and Gemcitabine HCl (S1149)?

  • 回答:

    Gemcitabine HCl is the HCl salt form of Gemcitabine. They have the same biological activities. The free base(S1714) dissolves better in DMSO, and the hydrochloride (S1149) dissolves better in water.

Related Antibodies

DNA/RNA Synthesis信号経路図

相関DNA/RNA Synthesis製品

Tags: Gemcitabine を買う | Gemcitabine ic50 | Gemcitabine 供給者 | Gemcitabine を購入する | Gemcitabine 費用 | Gemcitabine 生産者 | オーダーGemcitabine | Gemcitabine 化学構造 | Gemcitabine 分子量 | Gemcitabine 代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID